June 3, 2010
ChemoFx® Drug Response Marker Delivers Substantial Cost Savings
May 11, 2010
Jazz Pharmaceuticals Announces Pricing of Public Offering of Common Stock
May 7, 2010
Xanodyne Announces Renewed Focus on Pain Management Market
May 3, 2010
Corcept Therapeutics Updates Cushing's Syndrome Development and Recent Financing
April 22, 2010
Corcept Therapeutics Announces Exercise of Existing Warrants and Private Placement of Warrants
April 1, 2010
Xanodyne and Ferring Announce Co-Promote for Zipsor
March 19, 2010
PixelOptics Unveils Bold Marketplace Approach for Electronic Eyewear
February 23, 2010
Corcept Therapeutics Initiates a Phase 1 Study of CORT 108297
February 23, 2010
Solta Medical to Acquire Aesthera Corporation
February 18, 2010
Jazz Pharmaceuticals Announces FDA Acceptance of its New Drug Application for JZP-6 (sodium oxybate) for the Treatment of Fibromyalgia
January 11, 2010
Amarin Announces First Patients Enrolled in Two Phase 3 Clinical Trials for AMR101
January 8, 2010
Solta Medical to Raise $17.2 Million in Private Placement
January 5, 2010
Corcept Therapeutics Announces Four Anticipated Milestones for 2010
January 5, 2010
Panasonic Shikoku Electronics Joins PixelOptics in Development of Electronic Eye Glasses
December 15, 2009
Jazz Pharmaceuticals Submits New Drug Application for JZP-6 (sodium oxybate) for the Treatment of Fibromyalgia
November 16, 2009
Xanodyne Announces FDA Approval of Lysteda™ for Treatment of Women with Heavy Menstrual Bleeding
November 12, 2009
Xanodyne Expands U.S. Sales Force and Launches Zipsor™ Liquid Filled Capsules
October 29, 2009
Xanodyne Raises $50 Million in Equity Financing
October 13, 2009
Amarin Announces $70 Million Private Placement
October 13, 2009
Corcept Therapeutics Announces $18 Million Private Placement
September 4, 2009
Jazz Pharmaceuticals (JAZZ) Running On Buy From Smart Investor
August 3, 2009
Amarin Announces $3.0 Million Bridge Financing
July 9, 2009
Amarin Receives Special Protocol Assessment Agreement from the FDA for Phase 3 Mixed Dyslipidemia Trial
July 7, 2009
Jazz Pharmaceuticals Completes $7 Million Private Placement
June 10, 2009
Amarin Announces Results from Exploratory Phase 2a Study of EN101 in Myasthenia Gravis
May 26, 2009
Amarin Announces $2.6 Million Bridge Financing
May 6, 2009
Amarin Receives Special Protocol Assessment Agreement from the FDA for Phase 3 Cardiovascular Trial
April 8, 2009
Amarin's Marketing Authorization Application for AMR101 to Treat Huntington's Disease Accepted for Review by EMEA
March 30, 2009
Corcept Therapeutics Announces Fourth Quarter and Full Year 2008 Results and Update on Development Programs
March 20, 2009
PixelOptics and Transitions Optical Announce Partnership
March 1, 2009
Precision Therapeutics' Quarterly Newsletter
February, 23, 2009
Corcept Therapeutics: Data Demonstrates Metabolic Benefits of Adding Corlux® to Treatment with Risperdal®
February 16, 2009
PixelOptics Begins Wearer Trials of Electronic Focusing Eyewear
February 10, 2009
Aptus Endosystems Completes Enrollment in STAPLE-2 Pivotal Study
February 2, 2009
Corcept Therapeutics: Corlux Mitigates Weight Gain Associated with Risperdal
January 14, 2009
PixelOptics Announces New Patent Issuance Covering Proprietary Composite Lens Technology
January 8, 2009
Corcept Therapeutics: Trials Show Next-Generation GRII Receptor Antagonist Prevents and Reverses Weight Gain Associated with Use of Olanzapine
January 7, 2009
Aptus Endosystems Completes $30 Million Series C Financing
December 18, 2008
Amarin Opens U.S. R&D Office in Mystic, Connecticut
December 2, 2008
Corcept Therapeutics: Caroline Loewy Joins as Chief Financial Officer
November 10, 2008
Precision Therapeutics Secures $43 Million in Venture Capital Funding
October 27, 2008
InfaCare Raises $28 Million in Series B Financing to Advance Its Neonatal Pipeline
October 23, 2008
PixelOptics Closes on $30 Million Round of Financing
September 3, 2008
Corcept Therapeutics Continues Collaboration with Eli Lilly and Company
July 22, 2008
Amarin Proceeding to Phase 3 with AMR101 for Hypertriglyceridemia
July 18, 2008
VC Firm Longitude Capital Targets Life Sciences Industry
July 8, 2008
Longitude Capital closes $325 million life sciences fund
May 14, 2008
Amarin announces private placement for up to $60 million
May 1, 2008
Corcept Therapeutics Announces Promising Results of Human Microdosing Study of Selective GR-II Antagonist
March 17, 2008
Corcept Therapeutics announces $25.3mm private equity financing
|
